247 related articles for article (PubMed ID: 25981525)
1. A prospective, active haemovigilance study with combined cohort analysis of 19,175 transfusions of platelet components prepared with amotosalen-UVA photochemical treatment.
Knutson F; Osselaer J; Pierelli L; Lozano M; Cid J; Tardivel R; Garraud O; Hervig T; Domanovic D; Cukjati M; Gudmundson S; Hjalmarsdottir IB; Castrillo A; Gonzalez R; Brihante D; Santos M; Schlenke P; Elliott A; Lin JS; Tappe D; Stassinopoulos A; Green J; Corash L
Vox Sang; 2015 Nov; 109(4):343-52. PubMed ID: 25981525
[TBL] [Abstract][Full Text] [Related]
2. An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment.
Osselaer JC; Cazenave JP; Lambermont M; Garraud O; Hidajat M; Barbolla L; Tardivel R; Defoin L; Waller C; Mendel I; Raidot JP; Kandel G; De Meuter R; Fabrigli P; Dehenau D; Arroyo JL; Padrón F; Gouezec H; Corral M; Jacquet M; Sundin D; Lin L; Corash L
Vox Sang; 2008 May; 94(4):315-23. PubMed ID: 18248574
[TBL] [Abstract][Full Text] [Related]
3. A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment.
Osselaer JC; Messe N; Hervig T; Bueno J; Castro E; Espinosa A; Accorsi P; Junge K; Jacquet M; Flament J; Corash L
Transfusion; 2008 Jun; 48(6):1061-71. PubMed ID: 18346019
[TBL] [Abstract][Full Text] [Related]
4. An active hemovigilance program characterizing the safety profile of 7483 transfusions with plasma components prepared with amotosalen and UVA photochemical treatment.
Cazenave JP; Waller C; Kientz D; Mendel I; Lin L; Jacquet M; Propst M; Liu W; Corash L; Sundin D; Defoin L; Messe N; Osselaer JC
Transfusion; 2010 Jun; 50(6):1210-9. PubMed ID: 20113450
[TBL] [Abstract][Full Text] [Related]
5. Pathogen inactivation of double-dose buffy-coat platelet concentrates photochemically treated with amotosalen and UVA light: preservation of in vitro function.
Sandgren P; Diedrich B
Vox Sang; 2015 May; 108(4):340-9. PubMed ID: 25557354
[TBL] [Abstract][Full Text] [Related]
6. Prevention of transfusion-associated graft-versus-host disease with pathogen-reduced platelets with amotosalen and ultraviolet A light: a review.
Cid J
Vox Sang; 2017 Oct; 112(7):607-613. PubMed ID: 28833219
[TBL] [Abstract][Full Text] [Related]
7. Comparison of transfusion efficacy of amotosalen-based pathogen-reduced platelet components and gamma-irradiated platelet components.
Sigle JP; Infanti L; Studt JD; Martinez M; Stern M; Gratwohl A; Passweg J; Tichelli A; Buser AS
Transfusion; 2013 Aug; 53(8):1788-97. PubMed ID: 23176347
[TBL] [Abstract][Full Text] [Related]
8. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial.
van Rhenen D; Gulliksson H; Cazenave JP; Pamphilon D; Ljungman P; Klüter H; Vermeij H; Kappers-Klunne M; de Greef G; Laforet M; Lioure B; Davis K; Marblie S; Mayaudon V; Flament J; Conlan M; Lin L; Metzel P; Buchholz D; Corash L;
Blood; 2003 Mar; 101(6):2426-33. PubMed ID: 12456508
[TBL] [Abstract][Full Text] [Related]
9. Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a Chikungunya virus epidemic in Ile de La Réunion.
Rasonglès P; Angelini-Tibert MF; Simon P; Currie C; Isola H; Kientz D; Slaedts M; Jacquet M; Sundin D; Lin L; Corash L; Cazenave JP
Transfusion; 2009 Jun; 49(6):1083-91. PubMed ID: 19309473
[TBL] [Abstract][Full Text] [Related]
10. Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia.
Slichter SJ; Raife TJ; Davis K; Rheinschmidt M; Buchholz DH; Corash L; Conlan MG
Transfusion; 2006 May; 46(5):731-40. PubMed ID: 16686840
[TBL] [Abstract][Full Text] [Related]
11. Photochemical treatment of platelet concentrates with amotosalen hydrochloride and ultraviolet A light inactivates free and latent cytomegalovirus in a murine transfusion model.
Jordan CT; Saakadze N; Newman JL; Lezhava LJ; Maiers TT; Hillyer WM; Roback JD; Hillyer CD
Transfusion; 2004 Aug; 44(8):1159-65. PubMed ID: 15265119
[TBL] [Abstract][Full Text] [Related]
12. Amotosalen interactions with platelet and plasma components: absence of neoantigen formation after photochemical treatment.
Lin L; Conlan MG; Tessman J; Cimino G; Porter S
Transfusion; 2005 Oct; 45(10):1610-20. PubMed ID: 16181212
[TBL] [Abstract][Full Text] [Related]
13. Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial.
Snyder E; McCullough J; Slichter SJ; Strauss RG; Lopez-Plaza I; Lin JS; Corash L; Conlan MG;
Transfusion; 2005 Dec; 45(12):1864-75. PubMed ID: 16371039
[TBL] [Abstract][Full Text] [Related]
14. Pathogen-reduced platelets for the prevention of bleeding.
Butler C; Doree C; Estcourt LJ; Trivella M; Hopewell S; Brunskill SJ; Stanworth S; Murphy MF
Cochrane Database Syst Rev; 2013 Mar; (3):CD009072. PubMed ID: 23543569
[TBL] [Abstract][Full Text] [Related]
15. Amotosalen-HCl-UVA pathogen reduction does not alter poststorage metabolism of soluble CD40 ligand, Ox40 ligand and interkeukin-27, the cytokines that generally associate with serious adverse events.
Hamzeh-Cognasse H; Laradi S; Osselaer JC; Cognasse F; Garraud O
Vox Sang; 2015 Feb; 108(2):205-7. PubMed ID: 25334045
[TBL] [Abstract][Full Text] [Related]
16. Impact of platelet pathogen inactivation on blood component utilization and patient safety in a large Austrian Regional Medical Centre.
Amato M; Schennach H; Astl M; Chen CY; Lin JS; Benjamin RJ; Nussbaumer W
Vox Sang; 2017 Jan; 112(1):47-55. PubMed ID: 28001297
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial.
McCullough J; Vesole DH; Benjamin RJ; Slichter SJ; Pineda A; Snyder E; Stadtmauer EA; Lopez-Plaza I; Coutre S; Strauss RG; Goodnough LT; Fridey JL; Raife T; Cable R; Murphy S; Howard F; Davis K; Lin JS; Metzel P; Corash L; Koutsoukos A; Lin L; Buchholz DH; Conlan MG
Blood; 2004 Sep; 104(5):1534-41. PubMed ID: 15138160
[TBL] [Abstract][Full Text] [Related]
18. Clinical impact of amotosalen-ultraviolet A pathogen-inactivated platelets stored for up to 7 days.
Infanti L; Holbro A; Passweg J; Bolliger D; Tsakiris DA; Merki R; Plattner A; Tappe D; Irsch J; Lin JS; Corash L; Benjamin RJ; Buser A
Transfusion; 2019 Nov; 59(11):3350-3361. PubMed ID: 31574181
[TBL] [Abstract][Full Text] [Related]
19. [Photochemical inactivation of pathogens in platelets and plasma: five years of clinical use in routine and hemovigilance. Towards a change of paradigm in transfusion safety].
Cazenave JP
Transfus Clin Biol; 2011 Apr; 18(2):53-61. PubMed ID: 21474358
[TBL] [Abstract][Full Text] [Related]
20. Patient outcomes and amotosalen/UVA-treated platelet utilization in massively transfused patients.
Nussbaumer W; Amato M; Schennach H; Astl M; Chen CY; Lin JS; Corash L; Benjamin RJ
Vox Sang; 2017 Apr; 112(3):249-256. PubMed ID: 28198023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
